Ascelia Pharma AB (publ) (OM: ACE)
Health Care · Biotechnology · SE
Skr0.86
+5.68% today · -75.4% 1Y
Ascelia Pharma AB (publ) (OM: ACE) operates in the Biotechnology industry within the Health Care sector. The company is valued at $10.78M and employs 10 people.
Over the last twelve months the share price has lost 75.4%, trading between 0.46 and 3.55.
Tweenvest scores Ascelia Pharma AB (publ) across four factors: quality 35/100, value 38/100. Its strongest factor is value.
ACE price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $10.78M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.48
- Dividend yield
- —
- Beta (5Y)
- 0.77
- 52-week high
- Skr3.55
- 52-week low
- Skr0.46
- Avg volume (3M)
- —
- Shares outstanding
- 133.54M
- Employees
- 10
- Next earnings
- —
About Ascelia Pharma AB (publ)
Ascelia Pharma AB (publ) is a Swedish biotechnology company concentrating on the development of orphan drugs for cancer treatment. The firm is currently progressing Mangoral, an innovative non-gadolinium contrast agent, through Phase 3 clinical trials for magnetic resonance imaging (MRI) of the liver. Furthermore, it is advancing Oncoral, a novel oral chemotherapy tablet, which is in Phase 2 development for gastric cancer therapy. Ascelia Pharma has also entered into a clinical collaboration agreement with Taiho Oncology, Inc. to develop Oncoral in combination with LONSURF. The company was established in 2000 and has its headquarters situated in Malmö, Sweden.
- ISIN
- SE0010573113
- Founded
- 1999
- Listed since
- Mar 13, 2019
- Exchange
- OMX Nordic Exchange Stockholm
- Currency
- SEK
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| BioVie Inc.NasdaqCM: BIVI | $11.01M | $1.28 | -12.33% |
| GT Biopharma, Inc.NasdaqCM: GTBP | $11.01M | $5.96 | -2.30% |
| Lantern Pharma Inc.NasdaqCM: LTRN | $11.00M | $0.83 | -3.50% |
| CytoMed Therapeutics LimitedNasdaqCM: GDTC | $10.98M | $0.94 | +2.71% |
| Ceryvyn Therapeutics LimitedASX: CYV | $10.46M | AU$0.01 | +22.22% |
| Delta-Fly Pharma, Inc.TSE: 4598 | $10.40M | ¥111.00 | -5.13% |
| Theriva Biologics, Inc.NYSEAM: TOVX | $10.33M | $0.23 | +0.89% |
| Brainstorm Cell Therapeutics Inc.OTCPK: BCLI | $10.26M | $0.93 | -4.10% |
Figures last refreshed Oct 4, 2026.